Key Takeaways
- B. Riley reduced Oklo’s price target to $92 from $129 while maintaining its Buy recommendation
- Craig-Hallum dropped its target to $71 from $87 with a Hold rating, pointing to escalating capital requirements
- Needham slashed its target from $135 down to $73 but retained a Buy rating, suggesting approximately 20% potential gains
- CEO Jacob Dewitte and CFO Richard Bealmear each offloaded roughly 72,000 shares at $60 per share on March 13; insider sales totaled ~$170M over 90 days
- On a brighter note, Oklo’s Atomic Alchemy division secured a DOE Nuclear Safety Design Agreement and an NRC materials license
The past half-year has been challenging for Oklo’s shareholders. The nuclear energy provider, currently trading around $60.76, has declined 42% during this six-month stretch and sits significantly beneath its 52-week peak of $193.84.
Multiple Wall Street firms revised their price objectives downward this week after reviewing the company’s Q4 2025 financial results. While targets decreased, most analysts haven’t abandoned their positions — they’re simply adjusting expectations.
B. Riley lowered its objective from $129 to $92 while maintaining a Buy recommendation. The firm highlighted tangible business achievements: Department of Energy approvals for the Aurora facility at Idaho National Laboratory, a prepayment deal with Meta covering up to 1.2 gigawatts in Ohio, initial fuel facility development, and regulatory achievements for its Atomic Alchemy isotope division.
Needham similarly maintained its Buy stance while dramatically reducing its target from $135 to $73. This revised objective still suggests roughly 20% upside potential from present levels, and Wall Street’s consensus target hovers near $94.80 with a “Moderate Buy” rating overall.
Craig-Hallum adopted a more reserved position. The firm maintained a Hold rating and reduced its target from $87 to $71. The firm updated its projections to reflect elevated operating costs, expanded capital expenditures, and modified assumptions regarding future financing needs. It also excluded projected 2026 isotope revenue — likely under $5 million — from its forecast until additional information becomes available.
Rising Capital Requirements and Insider Transactions Dampen Investor Confidence
Oklo finished Q4 2025 holding $1.4 billion in cash reserves. Following the quarter’s conclusion, the company secured another $1.2 billion in capital. Management projects operating cash usage between $80 million and $100 million for 2026, alongside investing cash usage ranging from $350 million to $450 million.
Despite substantial cash holdings, the company reported a $97 million EBITDA loss over the trailing twelve-month period and a full-year 2025 operating deficit of $139.3 million. Wall Street doesn’t anticipate profitability this year.
Compounding concerns, CEO Jacob Dewitte divested approximately 72,960 shares on March 13 at $60 each, a sale totaling roughly $4.38 million. CFO Richard Bealmear sold 72,090 shares the same day at an identical price, generating around $4.33 million. Throughout the past 90 days, company insiders have sold approximately 2.07 million shares valued at roughly $170 million collectively. Insiders retain an 18.9% ownership stake.
Regulatory Achievements Provide Bright Spots
Not all developments are negative. Oklo’s Atomic Alchemy subsidiary obtained a DOE Nuclear Safety Design Agreement for its Groves isotopes test reactor. The division also secured an NRC materials and isotope license — marking the first NRC license Oklo has obtained through an acquired subsidiary.
The company’s Aurora reactor earned its initial design approval from the Department of Energy, a necessary milestone for advancing a 1.2-gigawatt power supply agreement with Meta, scheduled for delivery by 2034.
William Blair confirmed an Outperform rating. Cantor Fitzgerald maintained an Overweight designation with a $122 objective. Barclays holds an Overweight rating with an $82 target. Bank of America maintains a Buy rating with a $127 price objective.
Oklo’s 50-day moving average rests at $75.08 while its 200-day moving average sits at $95.27. The company maintains a market capitalization of approximately $9.49 billion.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
